| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Amgen is making significant advancements in drug development, particularly with its weight-loss drug MariTide and its potential applications for diabetes, cardiovascular conditions, and sleep apnea. Recent research has revealed that low-dose administration of MariTide may offer effective weight loss with fewer side effects, while innovative drug delivery methods are being explored to improve treatment outcomes. However, there are notable concerns regarding gastrointestinal side effects associated with MariTide, which could impact its acceptance and efficacy perception in the market. |
| The price action of Amgen (AMGN) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.2 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for AMGN since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.4, and the negative at -0.2 on 2025-06-24. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (2.2) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| AMGN | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-24 | 0%(0%) | 0 | 0% | 0.2 | 2.2 | -1 | |||||||
| 2025-05-13 | 0%(0%) | 0 | 0% | 0.3 | 2.9 | -1 | |||||||
| 2025-05-10 | 0%(0%) | 0 | 0% | 0.5 | 4.2 | -1 | |||||||
| 2025-05-09 | 0%(0%) | 0 | 0% | 0.5 | 4.2 | -1 | |||||||
| 2025-05-08 | 0%(0%) | 0 | 0% | 0.5 | 4 | -1 | |||||||
| 2025-05-07 | 0%(0%) | 0 | 0% | 0.6 | 4.5 | -1 | |||||||
| 2025-05-06 | 0%(0%) | 0 | 0% | 0.5 | 3.9 | -1 | |||||||
| 2025-05-05 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-05-04 | 0%(0%) | 0 | 0% | 0.5 | 3.9 | -1 | |||||||
| 2025-05-03 | 0%(0%) | 0 | 0% | 0.5 | 4 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-07-18 17:43:46 The company actively engages with investors and analysts during calls, reflecting transparency and strategic management regarding future prospects. |
| 2025-07-18 17:43:46 The need for a lower starting dose to mitigate side effects presents challenges in the development and acceptance of MariTide. |
| 2025-07-18 17:43:46 The articles discuss Amgen's plans to proceed with Phase 3 trials for MariTide, indicating an ongoing commitment to drug development. |
| 2025-07-18 17:43:46 Amgen's stock experienced a notable decline following mixed clinical trial results, reflecting investor concerns about the drug's future. |
| 2025-07-18 17:43:46 Articles highlight the potential of Amgen's weight loss drug MariTide, indicating optimism about its efficacy despite dosing concerns. |